Quick Navigation
I’ve been in biotech for over a decade – started as a bench scientist, then moved to venture. I’ve seen hype cycles, crashes, and quiet revolutions. So when someone asks me “What’s the next big thing?”, I don’t just parrot press releases. I look at where capital, talent, and real-world pain points converge.
Today, that convergence is happening at the intersection of AI, cell engineering, and synthetic biology. Forget the moonshot: the next big thing is making biology programmable and cheap. Let me walk you through the three pillars I’m betting on – and one dark horse that most people miss.
The AI Revolution in Drug Discovery
You’ve heard about AlphaFold and generative AI for molecules. But here’s the non‑consensus part: the real value isn’t in finding new drugs faster – it’s in killing bad ideas earlier. I’ve sat in too many portfolio reviews where a promising compound fails in Phase II after $100M spent. AI that can predict toxicity and off‑target effects with 80% accuracy is worth its weight in gold.
Take Recursion Pharmaceuticals – they use machine learning to screen thousands of compounds in silico before touching a pipette. Last year I visited their Salt Lake City lab. The CEO showed me a dashboard that prioritized 50 candidates for a rare disease. Normally that would take two years; they did it in six months. The catch? Their model still fails on novel targets. But if you’re an investor, look for AI startups that have proprietary data moats – not just algorithms.
Why Traditional Pharma Is Struggling to Adopt AI
Big pharma is like a supertanker. They have legacy data in incompatible formats, and their R&D teams are skeptical of black boxes. The next big thing isn’t just the AI – it’s the data infrastructure that makes AI work. Companies like Insitro are building platforms that combine genomics, imaging, and clinical data. That’s the real bottleneck.
Why Cell Therapy Is Still Underestimated
CAR‑T therapies for blood cancers are already on the market. But the next wave is allogeneic cell therapies – off‑the‑shelf products that don’t require extracting a patient’s own cells. That’s the unlock for solid tumors and autoimmune diseases.
I remember a conversation last spring with the CSO of a cell therapy startup. He told me their biggest challenge isn’t the biology – it’s the manufacturing reproducibility. Every batch of cells is slightly different, and regulators hate that. The companies that solve this – using automated bioreactors and real‑time quality metrics – will dominate. Look at Fate Therapeutics (iPSC‑derived NK cells) or Allogene Therapeutics. But be warned: the clinical data is messy. I’d wait for Phase II results before jumping in.
The Manufacturing Wall
I toured a GMP facility in Houston last year. The cleanroom cost $200M to build. The cell therapy industry desperately needs point‑of‑care manufacturing – small, automated units that can be deployed in hospitals. Several startups are working on this (e.g., Cellares). If they succeed, the cost of cell therapy could drop tenfold. That’s the real big thing.
Gene Editing: From CRISPR to Prime Editing
CRISPR‑Cas9 is old news. The next big thing in gene editing is prime editing and base editing – they allow precise single‑letter changes without cutting both DNA strands. That dramatically reduces off‑target risks.
I was at an ASGCT conference where a researcher from Prime Medicine showed data on correcting a mutation that causes sickle cell disease. The efficiency was only 15% – but that’s enough to cure many recessive disorders. The field is moving fast. However, my contrarian take: in vivo delivery is still the Achilles heel. The next big thing won’t be a new editor, but a better delivery vehicle – lipid nanoparticles or engineered AAVs that hit specific tissues. Watch Verve Therapeutics (lipid nanoparticle delivery for heart disease) – they’re the ones to beat.
The Dark Horse: Synthetic Biology
Most investors ignore synbio because the timelines are long and the hype has burned them before. But I’m convinced it’s the next platform technology, similar to what cloud computing did for software. The key is programmable cells that produce chemicals, materials, and even food.
Take Ginkgo Bioworks – they design microbes to produce everything from fragrances to cannabinoids. Their foundry can test thousands of designs per week. I visited their Boston headquarters in 2023; the automation is insane – robots pipetting 24/7. The problem? Their revenue is still mostly from partnerships, not products. But once they crack a high‑value molecule (like a sustainable aviation fuel), the margins will be huge.
Another example: Perfect Day makes animal‑free whey protein using fermentation. They’ve partnered with B2B food companies. This is real. My personal favorite is New Culture (casein for vegan cheese) – I’ve tasted their mozzarella, and it’s indistinguishable from dairy.
Where Synbio Falls Short
The hype around “digital biology” is overblown. Most synbio companies have terrible unit economics because fermentation scale‑up is brutally hard. The next big thing will be the strain engineering platform that dramatically reduces the time from design to production. Zymergen (now part of Ginkgo) tried and failed too fast. Learn from their mistakes: don’t invest until you see proven cost curves.
How to Invest in the Next Biotech Wave
If you’re a retail investor, don’t chase late‑stage private companies. The best risk/reward is in public small‑caps with a clear catalyst in the next 12 months. Here’s a simple framework:
- Platform vs. pipeline: Prefer companies that license their platform to others (like Ginkgo, but cheaper). They have recurring revenue and lower risk.
- Look for cash‑runway: Avoid companies with less than 12 months cash. Biotech is brutal – a financing can kill your stock.
- Follow the science: Read ASCO and JPMorgan abstracts. The best picks often get overlooked in the press.
Personally, I’m building a position in CRISPR Therapeutics (cash‑rich, prime editing pipeline) and Codexis (enzyme engineering for synbio). But I’m also short some overhyped AI‑drug discovery names that have no data. Be selective.
Frequently Asked Questions
I’m a retail investor with a small portfolio – what’s the safest biotech play?
Don’t chase the hype around CRISPR stocks directly. Instead, look at contract development organizations (CDOs) that service both gene therapy and AI drug discovery – they have lower risk because they get paid regardless of clinical success. Examples: Charles River Laboratories or WuXi AppTec. Not sexy, but steady.
Will AI replace human scientists in drug discovery?
Short answer: no. Long answer: AI will replace the boring parts – like hit identification and toxicity prediction – but it can’t design a clinical trial or negotiate with the FDA. The best scientists will use AI as a co‑pilot. The threat is for bioinformaticians who only do manual data processing.
What’s the biggest risk in investing in cell therapy?
Cytokine release syndrome and neurotoxicity haven’t gone away. For allogeneic products, there’s also the risk of immune rejection. My advice: only invest if the company has a clear plan for adverse event management, and read the safety data carefully. I’ve seen too many cell therapy stocks halve on a single patient death.
Should I invest in synthetic biology ETFs?
There aren’t pure synbio ETFs yet. The closest is ARK Genomic Revolution ETF (ARKG) – but it’s heavily weighted to gene sequencing and CRISPR. If you want targeted exposure, pick individual leaders like Ginkgo or Twist Bioscience. But be prepared for 30%+ volatility.
When will prime editing be commercially viable?
I expect the first prime editing therapy to enter Phase III by 2026, and approval around 2028. But that’s for a liver‑targeted disease. For other tissues, you’re looking at 2030+. Don’t bet the farm on it.
What’s one underrated subsector in biotech right now?
Microbiome therapeutics. Everyone burned out after Seres Therapeutics’ ups and downs, but new data on fecal transplants for autism and depression is compelling. The startup Kaleido Biosciences (now private) had interesting approaches. It’s too early for public investing, but keep an eye on Finch Therapeutics.
This article is based on my personal experience and research. It is not financial advice. All investments carry risk. I hold positions in some mentioned stocks as of writing.
Comments
0